Vimarsana
Biggest News Aggregation in the World

Page 5 - Arnaud Delepine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Arnaud Delepine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Arnaud Delepine Today - Breaking & Trending Today

Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines - Vimarsana News

Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines

Collaborative efforts aim to accelerate drug discovery and improve clinical success Agreement to utilize Exscientia's AI-based capabilities and personalised medicine platform from target identification

Exscientia : and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines - Form 6-K - Vimarsana News

Exscientia : and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines - Form 6-K

Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines * ... | January 7, 2022

Press Release: Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of Sanofi Seite 1 - Vimarsana News

Press Release: Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of Sanofi Seite 1

16.12.2021 -     Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of SanofiPARIS – December 16, 2021 - On December 15, 2021, the Board of Directors appointed Gilles Schnepp, an independent director of Sanofi, as Chairman ... Seite 1

Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaki - Vimarsana News

Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaki

Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session  Dupixent significantly improved skin clearance and reduced overall disease severity and itch in a Pivotal trial that met all primary and seco...

Sanofi - Aventis Groupe: Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH's plenary and late-breaking sessions - Vimarsana News

Sanofi - Aventis Groupe: Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH's plenary and late-breaking sessions

Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH's plenary and late-breaking